about
Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.Therapeutic inhibition of prolyl hydroxylase domain-containing enzymes in surgery: putative applications and challenges.Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability.Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categoriesValidation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tailLocal radicality and survival outcome of pancreatic cancer surgeryAssociation Between Pancreatic Fistula and Long-term Survival in the Era of Neoadjuvant ChemotherapyPrognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer
P50
Q36877896-360F805B-19F5-42CC-828C-63164F49B877Q38989150-B1739510-FE42-4B14-848C-A9B1E6ECEE8FQ47164606-3AAB6B4D-108E-4F6E-AB9D-FFFEC1B84FB1Q88185488-B9A23513-EACC-4A7E-BE89-E46FDB1AF6B7Q88604650-C138CB88-0780-4A42-B420-998EDEBC3226Q90245724-0AA9785B-E989-445E-AB98-5E294295E7CEQ92614397-0EE5CEDA-3174-4AC6-851C-FC10442F899DQ92674095-6A8AD2FE-06B6-4905-8876-57CCC5773395
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Thomas Hank
@en
Thomas Hank
@nl
type
label
Thomas Hank
@en
Thomas Hank
@nl
prefLabel
Thomas Hank
@en
Thomas Hank
@nl
P31
P496
0000-0001-8087-2295